巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Centessa Pharmaceuticals plc

    CNTA
    4.970
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Centessa Pharmaceuticals plc - 延遲價格・最後更新於 05/07 22:00
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    4.970
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    467.38
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    25.980 - 2.885
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Centessa Pharmaceuticals plc
    證券代碼
    CNTA.US
    所屬板塊
    Biotechnology
    公司業務
    Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
    發行量
    94020005
    公司總部
    1 Ashley Road, 3rd Floor, Altrincham
    公司網址
    https://www.centessa.com
    公司電話
    +44 2039206789
    暫無內容

    關於

    Centessa Pharmaceuticals plc(CNTA.US)所屬的行業板塊為Biotechnology。
    Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
    詳細公司背景可參考: https://www.centessa.com